Amylin Announces Preliminary Tabulation of Annual Meeting Results
June 02 2009 - 12:36PM
PR Newswire (US)
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) today announced that IVS Associates, Inc., the
independent Inspector of Elections for the Company's Annual Meeting
of Stockholders held May 27, 2009, has completed its preliminary
tabulation of shareholder votes. The preliminary tabulation
indicates that shareholders voted to re-elect eight of the
Company's current Directors to Amylin's Board of Directors - Adrian
Adams, Steven R. Altman, Teresa Beck, Daniel M. Bradbury, Karin
Eastham, Dr. James R. Gavin III, Dr. Jay S. Skyler, and Joseph P.
Sullivan, as well as voted to elect its two new independent
nominees, Paul N. Clark and Paulo F. Costa. In addition, Dr.
Kathleen Behrens and Dr. Alexander J. Denner, Director candidates
nominated by Eastbourne Capital Management, L.L.C. and Carl Icahn,
respectively, were also elected to the Board. Joseph C. Cook, Jr.,
Amylin's Chairman, and James N. Wilson, Amylin's Lead Independent
Director, were not re-elected to the Board. Separately, IVS also
reported the preliminary tabulation of the other proposals voted on
at the Annual Meeting: -- Approval of the Company's 2009 Equity
Incentive Plan. -- Approval of an increase of 1,500,000 shares in
the aggregate number of shares of the Company's common stock
authorized for issuance under the Company's 2001 Employee Stock
Purchase Plan. -- Ratification of the selection of Ernst &
Young LLP as the independent registered public accounting firm of
the Company for its fiscal year ending December 31, 2009. --
Rejection of Mr. Icahn's proposal to change the Company's
jurisdiction of incorporation from Delaware to North Dakota. The
Company issued the following statement: We thank all our
shareholders for their support and greatly appreciate the valuable
insights offered to our Board and management team. We are also
grateful for the significant contributions and guidance provided by
outgoing Directors Joe Cook and Jim Wilson. Their industry
knowledge, expertise and leadership have been important assets to
Amylin over their many years of service, and we wish them well in
their future endeavors. All of us at Amylin remain deeply committed
to building long-term value for all of our shareholders, especially
through the anticipated launch of exenatide once weekly, our
investigational therapy that has the potential to significantly
advance the treatment of type 2 diabetes. We look forward to
working with all our new Directors to bring transformational
medicines to patients and to drive sustainable and profitable
growth. Voting results on Director elections and all proposals will
be finalized once they are certified by the Inspector following a
customary review and challenge period. A final tally of the votes
will be published in the Company's next quarterly report on Form
10-Q which will be filed with the Securities and Exchange
Commission in August. About Amylin Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide
acetate) injection and BYETTA(R) (exenatide) injection. Amylin's
research and development activities leverage the Company's
expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is headquartered in San Diego,
California. Further information on Amylin Pharmaceuticals is
available at http://www.amylin.com/. Forward Looking Statements
This press release contains forward-looking statements about
Amylin, which involve risks and uncertainties. Our actual results
could differ materially from those discussed herein due to a number
of risks and uncertainties, including risks that BYETTA, SYMLIN or
exenatide once weekly may be affected by competition, unexpected
new data, safety and technical issues, or manufacturing and supply
issues; risks that our clinical trials will not be completed when
planned, may not replicate previous results or achieve desired
end-points; risks that our preclinical studies may not be
predictive; risks that our NDAs for product candidates or sNDAs for
label expansion requests may not be submitted timely or receive FDA
approval; and other risks inherent in the drug development and
commercialization process. Commercial and government reimbursement
and pricing decisions and the pace of market acceptance may also
affect the potential for BYETTA, SYMLIN or exenatide once weekly.
These and additional risks and uncertainties are described more
fully in the Company's most recently filed Form 10-Q. Amylin
disclaims any obligation to update these forward-looking
statements. CONTACTS: Alice Izzo Executive Director, Corporate
Affairs Amylin Pharmaceuticals, Inc. (858) 642-7272 or Steve
Frankel / Averell Withers Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449 DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT:
Alice Izzo, Executive Director, Corporate Affairs, Amylin
Pharmaceuticals, Inc., +1-858-642-7272, ; Steve Frankel, or Averell
Withers, both of Joele Frank, Wilkinson Brimmer Katcher,
+1-212-355-4449 Web Site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024